Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combination Therapy for BRAF-V600E Metastatic CRCm
- Status
- RECRUITING
- Phase
- PHASE2
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
- Status
- RECRUITING
- Phase
- PHASE1
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Study of BND-35 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE1
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- Status
- RECRUITING
- Phase
- PHASE2
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2